These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 1846463)

  • 1. Cytomegalovirus disease prophylaxis in seronegative recipients of kidneys from seropositive donors by combination of cytomegalovirus-hyperimmune globulin and low-dose acyclovir.
    MacDonald AS; Belitsky P; Cohen A; Lee S
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1355-6. PubMed ID: 1846463
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of cytomegalovirus disease in heart transplant recipients by prophylaxis with cytomegalovirus hyperimmune globulin plus oral acyclovir.
    Eisenmann D; Knipp H; Laube H; Stegmann T
    Transplant Proc; 1990 Oct; 22(5):2322-3. PubMed ID: 2171169
    [No Abstract]   [Full Text] [Related]  

  • 3. Reduction by combination prophylactic therapy with CMV hyperimmune globulin and acyclovir of the risk of primary CMV disease in renal transplant recipients.
    Nicol DL; MacDonald AS; Belitsky P; Lee S; Cohen AD; Bitter-Suermann H; Lowen J; Whalen A
    Transplantation; 1993 Apr; 55(4):841-6. PubMed ID: 8386404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of cytomegalovirus disease in renal allograft recipients.
    Balfour HH
    Scand J Infect Dis Suppl; 1991; 80():88-93. PubMed ID: 1725064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation.
    Valenza M; Czer LS; Pan SH; Aleksic I; Freimark D; Harasty DA; Admon D; Barath P; Blanche C; Trento A
    J Heart Lung Transplant; 1995; 14(4):659-65. PubMed ID: 7578172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
    Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and prophylaxis of cytomegalovirus infection and disease in seronegative patients receiving kidneys from seropositive donors.
    Cuhadaroglu S; Cohen B; Haberal M
    Transplant Proc; 1992 Dec; 24(6):2626-7. PubMed ID: 1334586
    [No Abstract]   [Full Text] [Related]  

  • 8. Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective?
    Goral S; Ynares C; Dummer S; Helderman JH
    Kidney Int Suppl; 1996 Dec; 57():S62-5. PubMed ID: 8941924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of cytomegalovirus disease in liver transplant patients treated prophylactically with combination cytomegalovirus hyperimmune globulin and ganciclovir.
    Prian GW; Koep LJ
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):54-5. PubMed ID: 7940977
    [No Abstract]   [Full Text] [Related]  

  • 10. Effectiveness of combination prophylaxis with cytomegalovirus hyperimmune globulin and acyclovir in the high-risk kidney transplant recipient.
    Uber L; Cofer J; Baliga P; Rajagopalan PR
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):42-3. PubMed ID: 7482818
    [No Abstract]   [Full Text] [Related]  

  • 11. [incidence of cytomegalovirus infections following transplantation of kidneys from seropositive and seronegative donors].
    Kaden J; Adamczyk G; Eichler C; Strobelt V; Groth J; Janisch W; May G
    Z Urol Nephrol; 1985 May; 78(5):267-71. PubMed ID: 2994321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients.
    Reddy SP; Handa A; Tan L; Devaney A; Hughes D; Mason P; Friend PJ; Darby CR
    Transpl Int; 2003 Oct; 16(10):726-9. PubMed ID: 12827230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
    Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G
    Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus infection in pediatric liver recipients. A virological survey and prophylaxis with CMV immune globulin and early DHPG treatment.
    Dussaix E; Wood C
    Transplantation; 1989 Aug; 48(2):272-4. PubMed ID: 2547257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of infection and acute rejection after cytomegalovirus immune globulin prophylaxis in renal transplantation.
    Basadonna G; Feria A; Perez R; Klein H; Sturges M; Colquhoun S
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):52-3. PubMed ID: 7940976
    [No Abstract]   [Full Text] [Related]  

  • 17. Significant reduction of cytomegalovirus (CMV) disease by prophylaxis with CMV hyperimmune globulin plus oral acyclovir.
    Einsele H; Vallbracht A; Friese M; Schmidt H; Haen M; Dopfer R; Niethammer D; Waller HD; Ehninger G
    Bone Marrow Transplant; 1988 Nov; 3(6):607-17. PubMed ID: 2850830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: a case-controlled study.
    Legendre C; Ducloux D; Ferroni A; Chkoff N; Valette C; Geffrier C; Rouzioux C; Kreis H
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1431-3. PubMed ID: 8382871
    [No Abstract]   [Full Text] [Related]  

  • 19. Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: comparison of the randomized and open-label trials.
    Snydman DR; Werner BG; Tilney NL; Kirkman RL; Milford EL; Cho SI; Bush HL; Levey AS; Strom TB; Carpenter CB
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1357-60. PubMed ID: 1846464
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival.
    Abraham KA; O'Kelly P; Spencer S; Hickey DP; Conlon PJ; Walshe JJ
    Ren Fail; 2008; 30(2):141-6. PubMed ID: 18300112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.